Physician profile
Robert Boostanfar
NPI 1336119353
$12,930.75
in general payments reported to CMS, 2019-2025
9 companies · $7,376 in 2025
The $7,376 reported for 2025 was more than what 96% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,976 · 2020: $89.47 · 2021: $28.73 · 2022: $56.26 · 2023: $216 · 2024: $188 · 2025: $7,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,651 · Food and Beverage: $1,929 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,651.10 |
| Food and Beverage | $1,929.21 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $5,170.29 | 2019-2025 | Menopur |
| Ibsa Institut Biochimique Sa | $4,563.69 | 2025 | |
| Granata Bio Corporation | $2,373.24 | 2025 | |
| Emd Serono, INC. | $348.63 | 2019-2025 | |
| Organon LLC | $300.23 | 2021-2025 | Ganirelix Acetate, Follistim Aq, Pregnyl |
| Merck Sharp & Dohme LLC | $137.18 | 2019-2020 | |
| Therapeuticsmd, INC. | $19.88 | 2019 | |
| Hologic Sales and Service, LLC | $17.61 | 2024 | Myosure Tissue Removal Device |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boostanfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.